You are here
- Home
- Therapy Areas
- Neuroscience
Open-Label Positron Emission Tomography Study with the Selective β Amyloid Radioligand [18F]AZD4694 to Assess the Effects of Varying Radioligand Mass on Binding Parameters in Healthy Volunteers and Patients with Alzheimer’s Disease
- Drug Name
- AZD4694
- Generic Name
- AZD4694
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- I
- Start Date
- Mar 23, 2011
- Study Name
- D2750C00002
- Study Id
- D2750C00002
- ClinicalTrials.gov ID
- NCT01325402
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
